Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 65.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 45,350 shares of the biotechnology company’s stock after acquiring an additional 18,003 shares during the period. Cubist Systematic Strategies LLC’s holdings in Enanta Pharmaceuticals were worth $588,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Board of Administration of Florida Retirement System acquired a new position in shares of Enanta Pharmaceuticals in the first quarter worth $118,000. Vanguard Group Inc. raised its holdings in shares of Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after acquiring an additional 134,292 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 1.3% in the first quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock worth $14,906,000 after acquiring an additional 10,952 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Enanta Pharmaceuticals in the first quarter worth $191,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 3.5% in the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock worth $36,579,000 after acquiring an additional 70,000 shares during the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Enanta Pharmaceuticals

In other news, insider Scott T. Rottinghaus sold 5,375 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the sale, the insider now owns 21,717 shares of the company’s stock, valued at $370,926.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 13.64% of the company’s stock.

Enanta Pharmaceuticals Trading Up 3.9 %

ENTA stock opened at $11.04 on Friday. The stock has a 50-day moving average price of $11.92 and a two-hundred day moving average price of $13.22. Enanta Pharmaceuticals, Inc. has a 12-month low of $8.08 and a 12-month high of $17.80. The company has a market cap of $233.82 million, a PE ratio of -1.77 and a beta of 0.58.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The firm had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. During the same quarter in the previous year, the business earned ($1.27) earnings per share. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. Equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ENTA has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday. JPMorgan Chase & Co. dropped their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research note on Tuesday, August 6th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday. Finally, Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.00.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.